Trial Profile
A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Onilcamotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors CHOSA Oncology; RhoVac
- 10 Feb 2023 According to a CHOSA Oncology media release, RhoVac AB changes name to CHOSA Oncology AB.
- 05 Oct 2021 Three-years follow up results presented in a RhoVac media release.
- 16 May 2021 New source identified and integrated European Clinical Trials Database (EudraCT2020-004705-31 ).